The use of high-dose per fraction radiotherapy (RT) delivered as stereotactic body radiotherapy is a standard of care for prostate cancer. It is hypothesized that high-dose RT may enhance or suppress tumor-reactive immunity.
The use of high-dose per fraction radiotherapy (RT) delivered as stereotactic body radiotherapy is a standard of care for prostate cancer. It is hypothesized that high-dose RT may enhance or suppress tumor-reactive immunity.